XJPX2342
Market cap18mUSD
Dec 30, Last price
176.00JPY
1D
-3.30%
1Q
-27.57%
Jan 2017
-74.04%
Name
Trans Genic Inc
Chart & Performance
P/E
726.31
P/S
0.23
EPS
0.24
Div Yield, %
2.83%
Shrs. gr., 5y
—
Rev. gr., 5y
33.42%
Revenues
13.08b
+14.47%
Net income
4m
P
CFO
-392m
L-72.56%
Dividend
Mar 28, 20250 JPY/sh
Profile
Trans Genic Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment Business segments. The company provides glycan synthesis and analysis services; non-clinical studies for pharmaceuticals, foods, cosmetics, chemical substances, etc., as well as various safety tests for foods, and pharmaceutical agents; and support for bioequivalence test, including clinical trials, pharmacokinetic measurements, and the preparation of clinical trial reports; as well as hospital support services. It also offers drug efficiency and pharmacological test and safety studies; sugar chain analysis and synthesis services; advice and support services, including M&A, business revitalization, business succession services; and contract production services, such as genetically modified mice, antibodies, protein hypers, and expressing cells, as well as sells mouse-related products and mouse models, and research reagents. The company was formerly known as Kumamoto Immunochemical Laboratories Inc. and changed its name to Trans Genic Inc. in April 2000. Trans Genic Inc. was incorporated in 1998 and is headquartered in Fukuoka City, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | |||||
Revenues | 13,083,458 14.47% | 11,429,684 -9.12% | 12,576,568 13.85% | ||
Cost of revenue | 13,041,194 | 11,490,848 | 10,778,599 | ||
Unusual Expense (Income) | |||||
NOPBT | 42,264 | (61,164) | 1,797,969 | ||
NOPBT Margin | 0.32% | 14.30% | |||
Operating Taxes | 39,093 | 108,094 | 907,680 | ||
Tax Rate | 92.50% | 50.48% | |||
NOPAT | 3,171 | (169,258) | 890,289 | ||
Net income | 4,085 -101.00% | (409,668) -121.83% | 1,876,340 243.47% | ||
Dividends | (83,818) | (100,906) | (52,103) | ||
Dividend yield | 2.06% | 1.80% | 0.71% | ||
Proceeds from repurchase of equity | (78,617) | (298,599) | |||
BB yield | 1.93% | 4.09% | |||
| Debt | |||||
Debt current | 929,984 | 679,462 | 744,423 | ||
Long-term debt | 1,361,833 | 1,786,876 | 1,137,012 | ||
Deferred revenue | (9,387) | (493) | |||
Other long-term liabilities | 51,924 | 68,457 | 68,463 | ||
Net debt | (316,005) | (1,099,611) | (2,846,877) | ||
| Cash flow | |||||
Cash from operating activities | (392,453) | (1,430,031) | 1,789,202 | ||
CAPEX | (265,668) | (306,276) | (532,050) | ||
Cash from investing activities | (280,928) | (216,017) | 981,869 | ||
Cash from financing activities | (342,689) | 484,981 | (1,183,198) | ||
FCF | (719,864) | (1,036,281) | 833,507 | ||
| Balance | |||||
Cash | 2,478,229 | 3,459,447 | 4,624,476 | ||
Long term investments | 129,593 | 106,502 | 103,836 | ||
Excess cash | 1,953,649 | 2,994,465 | 4,099,484 | ||
Stockholders' equity | 2,221,477 | 2,328,778 | 2,826,881 | ||
Invested Capital | 6,353,046 | 6,212,858 | 5,398,872 | ||
ROIC | 0.05% | 15.63% | |||
ROCE | 0.51% | 21.86% | |||
| EV | |||||
Common stock shares outstanding | 16,802 | 16,844 | 17,165 | ||
Price | 242.00 -27.11% | 332.00 -21.88% | 425.00 -30.21% | ||
Market cap | 4,065,998 -27.29% | 5,592,142 -23.35% | 7,295,257 -31.03% | ||
EV | 3,854,373 | 4,597,009 | 4,552,387 | ||
EBITDA | 192,657 | 122,351 | 2,025,929 | ||
EV/EBITDA | 20.01 | 37.57 | 2.25 | ||
Interest | 47,476 | 28,464 | 22,636 | ||
Interest/NOPBT | 112.33% | 1.26% | |||